Unknown

Dataset Information

0

Long-term Safety and Immunogenicity of a Tetravalent Dengue Vaccine Candidate in Children and Adults: A Randomized, Placebo-Controlled, Phase 2 Study.


ABSTRACT:

Background

We report long-term safety and immunogenicity of Takeda's tetravalent dengue vaccine candidate (TAK-003) in healthy children and adults living in dengue-endemic areas in Puerto Rico, Columbia, Singapore, and Thailand.

Methods

In part 1 of this phase 2, randomized, placebo-controlled trial we sequentially enrolled 1.5-45 year olds (n = 148) into 4 age-descending groups, randomized 2:1 to receive 2 doses of TAK-003 or placebo 90 days apart. In part 2, 1-11 year olds (n = 212) were enrolled and randomized 3:1 to TAK-003 or placebo groups. We assessed neutralizing antibody titers for the 4 dengue serotypes (DENV) up to month 36 in part 1, and symptomatic dengue and serious adverse events (SAEs) up to month 36 in both parts.

Results

At month 36, seropositivity rates were 97.3%, 98.7%, 88.0% and 56.0% for DENV-1, -2, -3 and -4, respectively. Seropositivity rates varied significantly for DENV-4 according to serostatus at baseline (89.5% in seropositives versus 21.6% in seronegatives). No vaccine-related SAEs were reported.

Conclusions

The trial demonstrated persistence of neutralizing antibody titers against TAK-003 over 3 years in children and adults living in dengue-endemic countries, with limited contribution from natural infection. TAK-003 was well tolerated.

Clinical trials registration

NCT01511250.

SUBMITTER: Sirivichayakul C 

PROVIDER: S-EPMC9071315 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Long-term Safety and Immunogenicity of a Tetravalent Dengue Vaccine Candidate in Children and Adults: A Randomized, Placebo-Controlled, Phase 2 Study.

Sirivichayakul Chukiat C   Barranco-Santana Elizabeth A EA   Rivera Inés Esquilín IE   Kilbury Jennifer J   Raanan Marsha M   Borkowski Astrid A   Papadimitriou Athanasia A   Wallace Derek D  

The Journal of infectious diseases 20220501 9


<h4>Background</h4>We report long-term safety and immunogenicity of Takeda's tetravalent dengue vaccine candidate (TAK-003) in healthy children and adults living in dengue-endemic areas in Puerto Rico, Columbia, Singapore, and Thailand.<h4>Methods</h4>In part 1 of this phase 2, randomized, placebo-controlled trial we sequentially enrolled 1.5-45 year olds (n = 148) into 4 age-descending groups, randomized 2:1 to receive 2 doses of TAK-003 or placebo 90 days apart. In part 2, 1-11 year olds (n =   ...[more]

Similar Datasets

| S-EPMC7644226 | biostudies-literature
| S-EPMC5049724 | biostudies-literature
| S-EPMC4559193 | biostudies-literature
| S-EPMC8196333 | biostudies-literature
| S-EPMC11487277 | biostudies-literature
| S-EPMC7410446 | biostudies-literature
| S-EPMC9994689 | biostudies-literature
| S-EPMC4889756 | biostudies-literature
| S-EPMC11797386 | biostudies-literature
| S-EPMC4648257 | biostudies-literature